HealthPfizer Says Elrexfio Reduced Progression Risk in Myeloma TrialBy Naomi CalderOct 27, 2026, 10:31 PM UTC
HealthMyeloma Foundation Launches U.S. Trial Network With Johnson & JohnsonBy Naomi CalderOct 22, 2026, 10:15 PM UTC
BusinessActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical DevelopmentBy Nasdaq OMXApr 18, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual MeetingBy Nasdaq OMXApr 11, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsBy Nasdaq OMXFeb 28, 2018, 12:30 PM UTC
BusinessActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationBy Nasdaq OMXFeb 8, 2018, 1:01 PM UTC
BusinessActinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research ProgramsBy Nasdaq OMXJan 8, 2018, 12:31 PM UTC
